An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age

Trial Profile

An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Hepatitis A vaccine inactivated (Primary) ; MMR-varicella zoster virus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Chickenpox; Hepatitis A; Measles; Mumps; Pneumococcal infections; Rubella
  • Focus Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 18 Nov 2008 Official title and actual patient number updated.
    • 27 Oct 2008 Trial end date changed from 1 Mar 2008 to 1 May 2008 as reported by Clinicaltrials.gov.
    • 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top